Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
García
Begoña García, Navarra ES
| Patent application number | Description | Published |
|---|---|---|
| 20110262480 | Method for producing multiple modifications in the chromosome of gram-negative bacteria and salmonella strains which are deficient in c-di-GMP synthesis obtained by said method - Method for producing multiple modifications in the chromosome of Gram-negative bacteria and | 10-27-2011 |
Esteban Martinez García, Navarra ES
| Patent application number | Description | Published |
|---|---|---|
| 20110104341 | METHOD FOR CLOSING THE END OF FOLDED TUBULAR CASINGS - The invention relates to a method for closing the end of shirred tubular casings which comprises deshirring a terminal portion of the tubular casing in the direction of the axis of the stick, turning over the deshirred terminal portion in order to insert same inside the casing, securing the deshirred terminal portion from inside the casing, rotating the terminal portion and flattening the rotated terminal portion. | 05-05-2011 |
Esteban Martinez García, Navarra ES
| Patent application number | Description | Published |
|---|---|---|
| 20110104341 | METHOD FOR CLOSING THE END OF FOLDED TUBULAR CASINGS - The invention relates to a method for closing the end of shirred tubular casings which comprises deshirring a terminal portion of the tubular casing in the direction of the axis of the stick, turning over the deshirred terminal portion in order to insert same inside the casing, securing the deshirred terminal portion from inside the casing, rotating the terminal portion and flattening the rotated terminal portion. | 05-05-2011 |
Natividad García, Barcelona ES
| Patent application number | Description | Published |
|---|---|---|
| 20120122868 | APAF-1 INHIBITOR COMPOUNDS - Derivatives of 2,5-piperazinedione of formula (I) are apoptotic peptidase activating factor 1 (Apaf-1) inhibitors, therefore they are useful as active pharmaceutical ingredients for the prophylaxis and/or treatment of a pathological and/or physiological condition associated with an increase of apoptosis. | 05-17-2012 |